ftzy.com.cn (PTHL): Rasio utang marang kapitalisasi buku

Logo korporat perusahaan Pheton Holdings (PTHL)

Pheton Holdings Ltd lacks pricing power as it implements brachytherapy software in PRC hospitals during the pilot phase. The company's technologies provide targeted tumor irradiation while protecting healthy tissues. The SaaS development model ensures high distribution margins. The current debt-to-equity ratio reflects borrowing dynamics, with the indicator reaching the level of 0.03.

PTHL Pheton Holdings: Utang marang nilai buku ing interval 06.09.2024 - 16.01.2026
Produk sing diprodhuksi Pheton Holdings

Pheton Holdings Ltd (PTHL) is strengthening its position in the Asian healthcare IT and pharmaceutical sector. This ratio compares total liabilities to equity, quantifying the financial stability of the expansion. The metric measures insolvency risk, determining the balance between aggressive growth and debt security. A decrease in this indicator minimizes the probability of bankruptcy but may slow the pace of innovation. By analyzing the company's debt load relative to its balance sheet equity, an investor assesses the efficiency of its leveraged financing management.

Perusahaan pesaing

Utang-utang marang kapitalisasi buku HLN (Haleon plc)|Utang-utang marang kapitalisasi buku kenvue.com KVUE|VRNA - Rasio utang marang kapitalisasi buku|Rasio utang marang aset resik MENS (Jyong Biotech Limited)|Ligand Pharma (LGND) - Rasio utang marang kapitalisasi buku|Utang marang nilai buku Amneal Corp|PRGO (Perrigo Company plc) - Utang-utang marang kapitalisasi buku|Utang-utang marang kapitalisasi buku alvotech.com|Utang marang nilai buku LQDA (Liquidia)|GLPG (Galapagos N.V.) - Rasio utang marang aset resik|Rasio utang marang kapitalisasi buku ANI Pharma ANIP|Afrezza (MNKD) - Utang-utang marang nilai buku|AMPH: Utang marang nilai buku|pacira.com - Utang marang modal buku|SPRY: Utang-utang marang kapitalisasi buku|Theravance Biopharma Inc - Rasio utang marang aset resik|AQST (Aquestive Pharma) - Utang-utang marang kapitalisasi buku|Utang-utang marang nilai buku scPharma SCPH|Rasio utang marang kapitalisasi buku Tectonic Therapeutic, Inc. (TECX)|TNXP (tonixpharma.com) - Rasio utang marang aset resik|Rasio utang marang kapitalisasi buku China SXT Pharmaceuticals, Inc. SXTC|EPRX (Eupraxia Pharmaceuticals, Inc.) - Rasio utang-utang marang kapitalisasi buku|BioHarvest - Utang-utang marang kapitalisasi buku|Rasio utang marang aset resik EXOZ (Invizyne)|ORMP: Utang-utang marang kapitalisasi buku|Utang-utang marang nilai buku Entera Bio (ENTX)|Utang marang nilai buku HYFT|ABVC (ABVC BioPharma Inc.) - Utang marang modal buku|Rasio utang marang kapitalisasi buku Cumberland Pharma (CPIX)|QNTM - Utang-utang marang nilai buku|Rasio utang marang kapitalisasi buku FibroGen, Inc. FGEN|TELO: Rasio utang marang nilai buku|RANI: Utang marang nilai buku|Rasio utang marang aset resik SNYR (Synergy CHC Corp)|RLYB: Utang-utang marang kapitalisasi buku|Lexaria Bioscience Corp. - Rasio utang marang aset resik|Rasio utang marang kapitalisasi buku Pulmatrix, Inc.|Utang-utang marang nilai buku Aptorum APM|Rasio utang marang kapitalisasi buku Lyra Therapeutics (LYRA)|Rasio utang marang kapitalisasi buku IBO (Impact BioMedical, Inc.)|Utang-utang marang kapitalisasi buku TNFA (TNF Pharmaceuticals, Inc.)|YCBD: Rasio utang marang nilai buku|PainReform Ltd. - Utang-utang marang kapitalisasi buku|Utang-utang marang aset resik Altamira Therapeutics CYTO|Lipella Pharmaceuticals, Inc. (LIPO) - Rasio utang marang kapitalisasi buku|Rasio utang marang nilai buku OPTN|PIRS (Pieris) - Utang-utang marang kapitalisasi buku|PROC - Utang marang aset resik|Rasio utang marang kapitalisasi buku Petros Pharmaceuticals (PTPI)|Utang-utang marang aset resik qlsyy.net|ACELYRIN - Utang marang nilai buku|Rasio utang marang aset resik TFFP